vs
China SXT Pharmaceuticals, Inc.（SXTC）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
硕腾的季度营收约是China SXT Pharmaceuticals, Inc.的2877.7倍（$2.4B vs $829.5K）。硕腾净利率更高（25.3% vs -96.8%，领先122.0%）。硕腾同比增速更快（3.0% vs 0.0%）。硕腾自由现金流更多（$732.0M vs $-1.8M）
中国SXT药业是一家聚焦中国本土市场的制药企业，主要从事中药类处方药、非处方药物及营养保健品的研发、生产与销售，服务覆盖临床医疗机构与大众健康消费两大板块。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
SXTC vs ZTS — 直观对比
营收规模更大
ZTS
是对方的2877.7倍
$829.5K
营收增速更快
ZTS
高出3.0%
0.0%
净利率更高
ZTS
高出122.0%
-96.8%
自由现金流更多
ZTS
多$733.8M
$-1.8M
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $829.5K | $2.4B |
| 净利润 | $-802.6K | $603.0M |
| 毛利率 | 16.2% | 70.2% |
| 营业利润率 | -76.9% | 31.9% |
| 净利率 | -96.8% | 25.3% |
| 营收同比 | 0.0% | 3.0% |
| 净利润同比 | 0.0% | 3.8% |
| 每股收益（稀释后） | — | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SXTCZTS
| Q4 25 | — | $2.4B | ||
| Q3 25 | $829.5K | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $829.5K | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
净利润SXTCZTS
| Q4 25 | — | $603.0M | ||
| Q3 25 | $-802.6K | $721.0M | ||
| Q2 25 | — | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | $-802.6K | $682.0M | ||
| Q2 24 | — | $624.0M | ||
| Q1 24 | — | $599.0M |
毛利率SXTCZTS
| Q4 25 | — | 70.2% | ||
| Q3 25 | 16.2% | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | 16.2% | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
营业利润率SXTCZTS
| Q4 25 | — | 31.9% | ||
| Q3 25 | -76.9% | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | -76.9% | 36.6% | ||
| Q2 24 | — | 33.0% | ||
| Q1 24 | — | 34.1% |
净利率SXTCZTS
| Q4 25 | — | 25.3% | ||
| Q3 25 | -96.8% | 30.0% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | -96.8% | 28.6% | ||
| Q2 24 | — | 26.4% | ||
| Q1 24 | — | 27.4% |
每股收益（稀释后）SXTCZTS
| Q4 25 | — | $1.37 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | $-0.25 | $1.50 | ||
| Q2 24 | — | $1.37 | ||
| Q1 24 | — | $1.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.1M | — |
| 总债务越低越好 | $105.0K | — |
| 股东权益账面价值 | $15.4M | $3.3B |
| 总资产 | $21.7M | $15.5B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资SXTCZTS
| Q4 25 | — | — | ||
| Q3 25 | $18.1M | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $18.5M | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
总债务SXTCZTS
| Q4 25 | — | — | ||
| Q3 25 | $105.0K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $952.3K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SXTCZTS
| Q4 25 | — | $3.3B | ||
| Q3 25 | $15.4M | $5.4B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | $15.0M | $5.2B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $5.1B |
总资产SXTCZTS
| Q4 25 | — | $15.5B | ||
| Q3 25 | $21.7M | $15.2B | ||
| Q2 25 | — | $14.5B | ||
| Q1 25 | — | $14.1B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | $31.0M | $14.4B | ||
| Q2 24 | — | $14.2B | ||
| Q1 24 | — | $14.3B |
负债/权益比SXTCZTS
| Q4 25 | — | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $893.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $732.0M |
| 自由现金流率自由现金流/营收 | -216.2% | 30.7% |
| 资本支出强度资本支出/营收 | 4.9% | 6.7% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | — | $2.3B |
8季度趋势，按日历期对齐
经营现金流SXTCZTS
| Q4 25 | — | $893.0M | ||
| Q3 25 | $-1.4M | $938.0M | ||
| Q2 25 | — | $486.0M | ||
| Q1 25 | — | $587.0M | ||
| Q4 24 | — | $905.0M | ||
| Q3 24 | $-1.4M | $951.0M | ||
| Q2 24 | — | $502.0M | ||
| Q1 24 | — | $595.0M |
自由现金流SXTCZTS
| Q4 25 | — | $732.0M | ||
| Q3 25 | $-1.8M | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
自由现金流率SXTCZTS
| Q4 25 | — | 30.7% | ||
| Q3 25 | -216.2% | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
资本支出强度SXTCZTS
| Q4 25 | — | 6.7% | ||
| Q3 25 | 4.9% | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
现金转化率SXTCZTS
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SXTC
暂无分部数据
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
